GWS
PRME icon

Glassman Wealth Services’s Prime Medicine PRME Stock Holding History

Glassman Wealth Services’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-103
Closed -$913 – 1410
2023
Q4 		$913 Buy
+103
New +$794 ﹤0.01% 1575

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Glassman Wealth Services's PRME Position: Q1 2024 in Review

Glassman Wealth Services sold out of Prime Medicine (PRME) in Q1 2024, closing a stake of 103 shares — an estimated $913 sold.

Glassman Wealth Services first reported a position in PRME in Q4 2023 and held it in 1 quarter. The position peaked at $913 in Q4 2023. 115 funds tracked by Wall St. Rank hold PRME as of Q1 2024.

  • Glassman Wealth Services reported no remaining Prime Medicine position as of Q1 2024 after selling out during the quarter.
  • Glassman Wealth Services sold 103 Prime Medicine shares in Q1 2024, an estimated $913.
  • Glassman Wealth Services first reported a position in Prime Medicine in Q4 2023 and held it in 1 quarter.
  • Glassman Wealth Services's Prime Medicine position peaked at $913 in Q4 2023.
  • 115 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2024.

Based on Glassman Wealth Services's 13F filing for Q1 2024, filed 3 May 2024.